Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qihuang Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Second Traditional Chinese Medicine Hospital for the treatment of dry age-related macular degeneration (AMD). The formula is specifically indicated for patients presenting with the TCM syndrome of liver-kidney yin deficiency and phlegm-stasis interminglement. It is a multi-herb botanical extract designed to tonify the liver and kidney, resolve phlegm, and remove blood stasis. In clinical evaluations, Qihuang Granules are studied for their ability to improve visual function, enhance retinal and choroidal blood flow, reduce drusen volume, and modulate inflammatory biomarkers and hemorheological parameters. It is typically compared against lutein supplementation in clinical trial settings to establish its efficacy in preserving vision and ocular microcirculation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qihuang granules.